ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES

Omar El-Agnaf; Nour Khaled Majbour; Nishant Vaikath

ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES

Omar El-Agnaf (Inventor)
, Nour Khaled Majbour (Inventor)
, Nishant Vaikath (Inventor)

QBRI - Neurological Disorders Research Center

Qatar Foundation for Education, Science, and Community Development

Research output: Patent

Abstract

The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated α-synuclein and uses thereof. Uses of anti-α-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of α-synuclein-associated neurodegenerative diseases, are also disclosed.

Original language	English
Patent number	WO2022060236
IPC	G01N 33/ 577 A I
Priority date	17/09/20
Publication status	Published - 24 Mar 2022

Cite this

@misc{9dab4777cbb6451e884a2b2481611083,

title = "ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES",

abstract = "The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated α-synuclein and uses thereof. Uses of anti-α-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of α-synuclein-associated neurodegenerative diseases, are also disclosed.",

author = "Omar El-Agnaf and Majbour, \{Nour Khaled\} and Nishant Vaikath",

year = "2022",

month = mar,

day = "24",

language = "English",

type = "Patent",

note = "WO2022060236; G01N 33/ 577 A I",

}

TY - PAT

T1 - ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES

AU - El-Agnaf, Omar

AU - Majbour, Nour Khaled

AU - Vaikath, Nishant

PY - 2022/3/24

Y1 - 2022/3/24

N2 - The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated α-synuclein and uses thereof. Uses of anti-α-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of α-synuclein-associated neurodegenerative diseases, are also disclosed.

AB - The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated α-synuclein and uses thereof. Uses of anti-α-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of α-synuclein-associated neurodegenerative diseases, are also disclosed.

M3 - Patent

M1 - WO2022060236

ER -

ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED α-SYNUCLEIN AGGREGATES

Abstract

Fingerprint

Cite this